www.belgiumatbious.be

Belgian PavilionBooth 5237June 23-26, 2014San Diego, USA

BELGIUM@BIO

BELGIUM@BIO

2

Introduction 4 -5

Exhibitors at BIO 2014 San Diego 6 -29

Organizers Belgian Pavilion 30 -33

Partners Belgian Pavilion 34 -35

Trade & Investment Offices 36-37

Table of Contents

3

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

4

Introduction

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world-known educational systems , a promising product pipeline , and Belgium’s unique central location in Europe.

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

Additional assets of Belgium include: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

WW

W.B

ELG

IUM

ATBI

OUS

.BE

5

Exhibitorsat BIO 2014San Diego

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

6

WW

W.B

ELG

IUM

ATBI

OUS

.BE

ACTOGENIX

ALTIUS

APITOPE INTERNATIONAL

ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases with a high medical need. With several ActoBiotics™ in various stages of clinical and preclinical development, ActoGeniX’s initial focus is on areas with unmet need in gastrointestinal, immunological and metabolic diseases.

ALTIUS is one of the largest and most dynamic full-service independent Belgian law firms with strong international focus. Our Life Science practice group has a proven track record advising clients on contentious and non-contentious matters in the life science and healthcare industry. Our cross practice structure enables us to devise fully integrated solutions to the issues confronted by our clients in the increasingly challenging regulatory and commercial environment of the life sciences sector.

Apitope focuses on immunotherapies for the treatment of autoimmune and allergic diseases, including multiple sclerosis, factor VIII intolerance, uveitis and Graves’ disease. Apitope has a discovery platform which enables the selection of highly specific disease-modifying peptide therapies. These therapies selectively reinstate immune tolerance to the disease target of interest. Apitope has generated a pipeline of 6 clinical and preclinical programmes. The lead programme is partnered with Merck Serono.

www.actogenix.com

www.altius.com

www.apitope.com

Bio-incubatorTechnologiepark 49052 Ghent Belgium

Phone: +32 9 261 06 00

Tour & TaxiAvenue du Port 86c b4141000 Brussels Belgium

Phone: +32 2 426 14 14

BioVilleAgoralaan Building A-bis3590 Diepenbeek Belgium

Phone: +32 11 28 69 00

7

ARGEN-X

ASCLEPIA OUTSOURCING SOLUTIONS

ASEPTIC TECHNOLOGIES

arGEN-X uses its proprietary SIMPLE Antibody™ platform to identify human antibodies with unique functional properties and first / best in class therapeutic development potential – especially in the complex, high value disease target space. Focused on oncology and autoimmunity, arGEN-X applies its suite of Fc engineering technologies to tailoring its products for maximum efficacy, optimal dosing, convenience of administration and cost effectiveness.

Asclepia offers medicinal chemistry oriented research and services by designing and delivering innovative, therapeutically relevant, drug-like compounds. Asclepia offers focused libraries, and has in depth expertise in the coordination of virtual discovery programs. Strong expertise in outsourcing drug discovery through its large network of CRO’s, biotechs and academic science providers.

Aseptic Technologies develops and manufactures innovative aseptic fill and finish equipment for the BioPharmaceutical industry.The Closed Vial and the associated Filling Lines provide safer & easier sterility assurance for aseptic filling operations.Filling of the ready-to-fill vials is performed by a special needle piercing the stopper (then immediately resealed by a laser).Benefits are: uncompromised sterility even during storage at extremely low temperature, better safety during whole supply chain and cost reduction.

www.argen-x.com

www.asclepia.com

www.aseptictech.com

Technologiepark 309052 Ghent Belgium

Phone: +32 9 243 40 78

Damvalleistraat 499070 Destelbergen Belgium

Phone: +32 468 13 70 14

Rue Camille Hubert 75032 Gembloux Belgium

Phone: +32 81 409 410

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

8

BETA-CELL

BIOCARTIS

BIOLOG EUROPE

Beta-Cell is a spin-off from the Diabetes Research Center of the Vrije Universiteit Brussel. Beta-Cell focuses on the development of cell-based products for the treatment of diabetes. The company is developing BetaGRAFT®, an encapsulated porcine beta cell graft as an Advanced Medicinal Therapy Product. Beta-Cell has a long expertise in production and characterization of the cell preparations and adopts collaboration agreements to ensure complementary expertise such as encapsulation.

Biocartis develops and commercializes novel, broadly applicable molecular diagnostics and immunodiagnostics solutions combined with high-value clinical assay menus. The flagship product is a molecular diagnostics system comprising an instrument and disposable cartridges. Capable of detecting up to twenty-five nucleic acid biomarkers from a wide variety of sample types with truly sample-in result-out functionality, it offers fast and high quality care at the point of need.

Biolog Europe is a Belgian non-profit organization that helps biopharma and medical devices companies to expand on the European market or manage all the related challenges in an appropriate way. Through the Belgian bio-business environment, companies can find a top location to find partners, establish a subsidiary or relocate their activities. Our team provides support in business development challenges, while collaborating with all support organizations and sector federations

www.beta-cell.com

www.biocartis.com

www.biologeurope.com

I&I Center BrusselsZ1 Researchpark 3101731 ZellikBelgium

Phone: +32 2 477 43 49

Generaal De Wittelaan 11 B32800 MechelenBelgium

Phone: +32 15 63 26 00

LIEGE AIRPORT – Building 524460 Grace-Hollogne Belgium

Phone: +32 4 225 50 66 WW

W.B

ELG

IUM

ATBI

OUS

.BE

9

BIOMEDICAL SYSTEMS

BIOPARK CHARLEROI BRUSSELS SOUTH

BIOVILLE

Biomedical Systems is the first and only core lab to centralize the five primary clinical trial services: Imaging, Cardiac, Pulmonary, ePRO and Scientific Affairs, efficiently supporting regulatory approval processes. Not a manufacturer, we offer the broadest equipment selection to best meet trial needs. The longest privately held clinical trial service global provider, we deliver quality data, on-time to support successful study execution.

The Biopark is a centre of excellence for the biotechnology sector. Bringing together two universities, the Université Libre de Bruxelles (ULB) and the Université de Mons (UMONS), the centre is the home of a wide range of companies and institutions involved in different stages of the scientific innovation chain.The Biopark in a nutshell: 800 people, 6 research centres, 30 companies, an incubator, a knowledge transfer office and a lifelong learning centre.

BioVille is a full service investor/incubator, located in Flanders, Belgium, with the mission to support innovative life sciences projects and companies. As part of the venture capital group LRM, we offer laboratory and office infrastructure in combination with flexible financing modalities as well as extended technical, administrative and management support services.

www.biomedsys.com

www.biopark.be

www.bioville.be

Chaussée de Wavre 19451160 Brussels Belgium

Phone: +32 3 661 20 70

Université Libre de BruxellesRue Adrienne Bolland 8b26041 Gosselies Belgium

Phone: +32 2 650 98 69

Agoralaan Building A bis3590 DiepenbeekBelgium

Phone: +32 11 28 69 00

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

10

BIOXODES

CARDIO 3 BIOSCIENCES

CER GROUPE

Bioxodes is developing a portfolio of high value products derived from natural sources. The company’s lead product is Ir-CPI, a contact phase inhibitor with a range of potential therapeutic applications. In haemostasis, Ir-CPI is potentially the world’s first injectable antithrombotic able to provide ischemic protection without interruption during and after acute procedures in all patient groups without causing high levels of bleeding and without needing to be reversed orwashed out.

Cardio3 BioSciences is a leading biotech company focused on the discovery and development of regenerative, protective and reconstructive therapies for cardiac diseases by exploiting the breakthrough Cardiopoiesis platform, which is based on fundamental research conducted at Mayo Clinic (US). The company also developed C-Cathez®, an injection catheter with superior efficiency of delivery of bio-therapeutics into the myocardium.

CER Groupe is a Belgian CRO providing many services and developing partnerships with biotech and pharmaceutical companies in the pre-clinical and monoclonal antibody fields.

Preclinical activities:• Development and validation of pre-clinical models in

cell therapy, cancerology, infectiology and immunology• Dedicated solution to your studies

Antibodies activities:• Development, production and engineering of murine

and human monoclonal antibodies• Development of Elisa and PCR assays

www.bioxodes.com

www.c3bs.com

www.cergroupe.be

Parc d’activités du WEXRue de la Plaine 116900 Marche-en-Famenne Belgium

Phone: +32 71 348 590

Rue Edouard Belin 121435 Mont-Saint-Guibert Belgium

Phone: +32 10 39 41 00

Rue du Carmel 16900 Marloie Belgium

Phone: +32 84 22 02 11 WW

W.B

ELG

IUM

ATBI

OUS

.BE

11

COMPLIX

CURAVAC

DE CLERCQ & PARTNERS

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

CuraVac is a biotech company focused on bringing new therapeutic vaccines for autoimmune diseases to the patients. The first vaccine, Designated Orphan Drug, is a therapy for myasthenia gravis (MG). Last year CuraVac created MYASTERIX, a consortium of 4 companies and one University Medical Center, to conduct phase 1 (2015) and phase 2 (2017) in a 5 year program of $10 million that is 80% subsidized by the European Union FP7 R&D Program.CuraVac is looking for financing and strategic alliances.

De Clercq & Partners provides intellectual property services with a particular focus on patents in life sciences and biotechnology and related fields such as pharmaceuticals, medical chemistry, medical devices, diagnostics and screening methods, bioinformatics, and agricultural and veterinary sciences. De Clercq & Partners has offices in Sint-Martens-Latem and Heverlee (Leuven).

www.complix.com

www.curavac.com

www.dcp-ip.com

Technologiepark 49052 Ghent Belgium

Phone: +32 9 261 69 40

Av. de Villefranche 801330 Rixensart Belgium

Phone: +32 2 686 04 40

Edgard Gevaertdreef 10 a9830 St Martens Latem Belgium

Phone: +32 9 280 23 40

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

12

DELPHI GENETICS

DIFFERDING CONSULTING

DROIA

Founded in 2001, Delphi Genetics offers custom services and technologies in Molecular biology, Gene expression and Antibody development. The patented StabyExpress® technology developed by Delphi Genetics and licensed to Sanofi-Pasteur, GSK and Merck-MSD, improves the yield of recombinant protein without the use of antibiotics, thus complying with the latest FDA and EMEA standards. It is also usable for DNA vaccines and is combined to antigen-presentation technology to develop antibodies.

Differding Consulting advises biotech and pharma companies on improving productivity and innovation in preclinical R&D by partnering and outsourcing Drug Discovery activities, with a focus on India and China: assistance in optimizing outsourcing practices; identification of opportunities for strategic collaborations; selection of reliable partners and contract research organizations through a well-established network; assistance in contract negotiation, performance and alliance management.

DROIA is a hands-on investment company, focused on developing cancer therapies. DROIA has a close relationship with ACF, a not-for-profit organization.We are therefore extremely dedicated to the fightagainst cancer, all while creating shareholder value.

DROIA was founded in 2011 and has to day made 5 investments. We are data driven and invest in breakthrough potential. Our investments can be early stage but with a clear road to clinical development; several of our companies are clinical stage.

www.delphigenetics.com

www.differding.com

www.droiagroup.com

Rue Antoine de Saint-Exupéry 56041 Gosselies Belgium

Phone: +32 71 25 10 00

Route de Blocry 551348 Louvain-la-Neuve Belgium

Phone: +32 10 45 46 04

Boechoutlaan 2211853 Strombeek Bever Belgium

Phone: +32 2 880 67 30 WW

W.B

ELG

IUM

ATBI

OUS

.BE

13

EEBIC

EMBI TEC EUROPE

ESPERITY

EEBIC is an incubation structure for young, innovative companies. It offers housing and services supporting business planning, incorporation, financing and development of companies active in domains as high tech, biotech, medical device, …EEBIC finally also opens its networks of specialists invery diverse competence fields for its clients.

Embi Tec provides precast agarose and polyacrylamide gels for nucleic acid analysis and purification as well as the RunOne Electrophoresis System.A new line of compact lighting products like the 96-well/384-well LightOne Illuminators, ViewOne LabLite and PrepOne Sapphire are also available.Embi Tec Europe is located in Belgium and ships products from there to the European customers.This centralized European warehouse makes it easy and economical for ordering and delivering in Europe.

Esperity is the first multilingual platform allowing cancer patients to connect with each other while managing their health evolution. For healthcare actors, the platform allows the collection of patient reported outcome data. This data includes quality of life measures, adverse events and treatment information. Esperity can also function as a communication channel for patient education purposes. For patients, Esperity is a tool to become more empowered during the treatment process by reducing social isolation and encouraging them to track their condition.

www.eebic.be

www.embitec.com

www.esperity.com

Avenue Joseph Wybran 401050 Brussels Belgium

Phone: +32 2 529 58 11

Nieuwstraat 992560 Kessel Belgium

Phone: +32 475 36 68 34

Clos Chapelle-aux-Champs 30b 1.3030 (C/O BLSI)1200 Brussels Belgium

Phone: +32 476 24 10 86

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

14

EUROGENTEC

FLUIDDA

FORMAC PHARMACEUTICALS

Eurogentec is a contract manufacturing organization providing custom products and services to researchers in the research, diagnostic and biopharmaceutical sciences. The company operates under ISO 9001, ISO 13485 and injectable GMP quality systems. The close collaboration between Eurogentec’s two business units (Genomics and Proteomics BU and Biologics BU) is Eurogentec’s unique capability to fully support drug development projects from early R&D to commercial phases.

Together on a mission to accelerate respiratory drug and device development worldwide.FLUIDDA is the leading company in the research and development of imaging biomarkers to enhance drug development and patient care. Collaboration with universities and medical research centers resulted in clinical trials including a total of 750 patients.These trials proved the higher sensitivity of this novel approach over existing standard outcome parameters such as spirometry in the respiratory field.

Formac is a leading drug delivery company offering a unique mesoporous silica-based technology to enhance the oral bioavailability of poorly water-soluble drugs. The company is persuing a dual business model with partnering for NCE developments and developing reformulation products. Since its incorporation Formac has signed more than 40 feasibility agreements . To date, Formac is the only company that demonstrated the clinical relevancy of the silica based technology in a clinical setting.

www.eurogentec.com

www.fluidda.com

www.formacpharma.com

Rue du Bois Saint Jean 54102 Seraing Belgium

Phone: +32 43 72 74 00

Groeningenlei 1322550 Kontich Belgium

Phone: +32 3 450 87 20

Gaston Geenslaan 23001 Heverlee Belgium

Phone: +32 16 75 13 70 WW

W.B

ELG

IUM

ATBI

OUS

.BE

15

GALAPAGOS

GSK VACCINES

ICOSA EUROPE

Galapagos is a mid-size biotechnology company specialized in the discovery and development of small molecule therapies with novel modes-of-action. The Company is progressing GLPG0634, as well as one of the largest novel mode of action pipelines in biotech, with four programs in clinical research, 6 pre-clinical candidates and over 25 discovery programs. The Galapagos Group has about 400 employees and operates facilities in four European countries, with global headquarters in Mechelen, Belgium.

GSK is the world’s leading vaccine company. We are active in vaccine research, development and production with over 30 vaccines approved and at least 15 more in development. Our portfolio includes vaccines to prevent potentially life-threatening or crippling illnesses. In 2012, we distributed nearly 900 million doses of vaccine to both the developed and the developing world. We have more than 100 ongoing scientific collaborations.

ICOSA Europe is an IP Law firm devoted to servicing all areas of Life Sciences including Biotechnology, Chemistry, Pharmacy, Agrifoods, Cosmetics, Biomedical and Greentech sectors.The specificity of ICOSA Europe lies in its ability to design tailor-made IP strategies to serve the business purposes of its clients, including acquiring and defending patent rights, obtaining SPCs, and evaluating IP assets through patentability and freedom-to-operate studies, prior art searches or due diligences.

www.glpg.com

www.gsk.com

www.icosa-europe.com

Generaal De Wittelaan L11 A32800 Mechelen Belgium

Phone: +32 15 34 29 00

Avenue Fleming 201300 Wavre Belgium

Phone: +32 10 85 51 11

Clos Chapelle-aux-Champs 30 (c/o BLSI)b 1.30.30 (Suite 737, 7#)1200 Brussels Belgium

Phone: +32 2 880 62 48

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

16

IMEC

I-TECH INCUBATOR

ITEOS THERAPEUTICS

Imec is Europe’s leading independent research center on nanoelectronics, smart integrated systems, biomedical electronics, photovoltaics, organic electronics, power electronics & photonics. Imec, VIB, and KU Leuven set up a joint basic research initiative to unravel the neuronal circuitry of the human brain: Neuroelectronics Research Flanders (NERF).

i-Tech Incubator is an incubation structure for young, innovative companies. It offers housing and services supporting business planning, incorporation, financing and development of companies active in domains as biotech, medical device, engineering, green and clean technology, ....i-Tech Incubator finally also opens its networks of specialists in very diverse competence fields for its clients (legal, financial, scientific).

iTeos Therapeutics, a spin off of the Ludwig Cancer Research and University of Louvain, aims to improve current cancer therapies by combination with small molecules immunomodulators impacting on the immunosuppressive properties of the tumor microenvironment. iTeos plans to complete the preclinical development of indoleamine-2,3-dioxygenase (IDO1) and tryptophan-2,3 dioxygenase (TDO2) drug candidates by 2016. Currently iTeos has obtained potent compounds with activity in rodent PK-PD models.

www.imec.be

www.i-tech-incubator.be

www.iteostherapeutics.com

Kapeldreef 753001 Leuven Belgium

Phone: +32 16 28 12 11

Rue Auguste Piccard 486041 Gosselies Belgium

Phone: +32 71 91 99 50

Rue Auguste Piccard 486041 Gosselies Belgium

Phone: +32 71 919 934 WW

W.B

ELG

IUM

ATBI

OUS

.BE

17

JANSSEN PHARMACEUTICA

KU LEUVEN R&D (LRD) / CENTRE FOR DRUGDESIGN AND DISCOVERY (CD3)

LIEU

Janssen Pharmaceutica and other companies on our campus are part of the worldwide Janssen Pharmaceutical Group. Medicinal drugs for the benefit of patients, doctors and other health care professionals are discovered, developed and marketed on our campus. We mainly operate in the pathological areas of neurosciences, oncology, infectious diseases, and vaccines.The values described in our company code, Our Credo, are thereby a solid guideline. Our commitment and an open mind for innovation are our driving forces.

KU Leuven Research & Development (LRD) is the TTO of the KU Leuven and is dedicated to building bridges between science and industry, and to transferring knowledge and technologies from KU Leuven to the marketplace. The Centre for Drug Design and Discovery (CD3) is a technology transfer platform and investment fund created by LRD and the European Investment Fund. CD3 focuses on the discoveryof new and innovative small molecule drugs in collaboration with academic research groups or small companies andaims to create partnerships with biotech and pharma companies based on innovative drug discovery projects.

LIEU (LIaison Entreprises-Universités), the network of Technology Transfer Professionals grants you access to the skills of over 1000 labs and 7500 researchers of the Belgian French-speaking Universities and Higher Education Institutions.Within that framework it is the task of LIEU “Biotech Group” to carry out the specific missions of the network in the health and life sciences field; it acts as the entry point of the network.LIEU facilitates your access to the expertise of its network members

www.janssenpharmaceutica.be

http://lrd.kuleuven.be • www.cd3.eu

www.reseaulieu.be

Turnhoutseweg 302340 Beerse Belgium

Phone: +32 14 60 21 11

Waaistraat 6 bus 51053000 Leuven Belgium

Phone: +32 16 32 64 84

Passage des Déportés 25030 Gembloux Belgium

Phone: +32 71 37 86 56

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

18

MARBLE PHARMA CONSULT

NOVADIP BIOSCIENCES

NOVOSANIS

MARBLE PHARMA CONSULT offers expert support to companies outsourcing drug substance and/or aseptic drug product process & analytical development, validation and manufacturing activities• CDMO identification, selection and qualification;

integrated (international, cross-cultural) project & relationship management

• CMC scope supervision• Long-term or project-based lean, pragmatic

consultancy model• Complex API (highly active, peptide, cytotoxic,

conjugate…) and aseptic finished DP

NOVADIP BioSciences design, develop and bring to the market innovative Stem Cell-based Therapies for Regenerative Medicine, and more specifically for severe orthopaedic conditions. Creost® provides innovative treatments for severe bone healing disorders and bone defects. Key benefits of Creost®: minimally invasive procedure (stem cells from fat tissue), high capacity of differentiation, same properties as a real bone, easy-to-use without any scaffold, autologous and allogenic approaches.

Novosanis designs, develops and manufactures medical devices for a variety of applications ranging from injection appliances to in vitro diagnostics. Our goal is to improve health and patient care and offer a better quality of life through innovative technologies. Novosanis is a newly founded spin-off company of the University of Antwerp.

www.marblepharmaconsult.com

www.novadip.com

www.novosanis.com

Rue du Village 51A1380 Lasne Belgium

Phone: +32 496 200 726

Chemin du Cyclotron 61348 Louvain-la-Neuve Belgium

Phone: +32 10 77 92 20

Lange Winkelstraat 262060 Antwerp Belgium

Phone: +32 3 485 50 16

novosanis

WW

W.B

ELG

IUM

ATBI

OUS

.BE

19

ONTOFORCE

OSBORNE CLARKE

OUAT!

Ontoforce is a Belgian start-up that develops and implements innovative technologies to improve information flows and information management. Our activities mainly evolve around disqover, a user-friendly search engine that uses semantic technology to establish smart links. This tool makes you discover new data that truly helps you forward. One of ontoforce’s main goal is to use this technology to make drug discovery around the world more effective. Ontoforce has offices in Ghent and Hasselt.

Osborne Clarke is an international law firm and a well-known adviser to companies in the Life Science and Healthcare sector. We have a track record of advising on mid-to-high value M&A, significant disputes, small-to-major fundraisings and commercial transactions, regionally, nationally and internationally. Our client base includes big Pharma, biotechs, spin-outs, financiers, VCs and private equity houses. We have local life science capability across Europe and the US.

OUAT! is on a mission to support technology innovation and make it live by facilitating its acceptance. With its Biotechnology and Marketing expertise, OUAT! is able to identify and understand the value of complex scientific advances to deliver simple and integrated marketing tools that sell. Our team is made up of highly skilled Marketing Architects who act as an interface between our customers and first rate contractors. Spend time on your innovation, we take care of your marketing.

www.ontoforce.com

www.osborneclarke.com

www.ouat.eu

Kerkstraat 1089050 Gentbrugge Belgium

Phone: +32 479 48 21 18

Avenue Marnix 231000 Brussels Belgium

Phone: +32 2 515 93 00

Rue d’Alost 71000 Brussels Belgium

Phone: +32 491 37 04 32

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

20

OVIZIO

PHARA

PROGRESS PHARMA

Ovizio, spin-off of the “Université Libre de Bruxelles” (ULB), develops and markets a 4D quantitative imaging platform technology based on Holographic Microscopy with a primary focus on Bioprocessing, Life Science Research and Diagnostics. Ovizio’s technology unifies real-time quantitative imaging with speed and a label-free, non-invasive approach. Our advanced devices break the barriers between the traditional speed of flow cytometry and the resolution of classical microscopy.

RELIABLE, RESOURCEFUL, RESPECTFUL AND REGULATORYWISE

PhaRA is a consultancy firm in EU Regulatory Affairs,providing strategic and hands-on support (CTA, PIP,Orphan Drug, Scientific Advice, CP/DCP/MRP, MAA, etc).By concentrating exclusively on regulatory affairs,we offer in-depth knowledge, insight, and experience. We can assist the regulatory affairs department, oroperate as independent driver of specialized regulatory activities, or even function as a fully-staffed regulatory department.

WE LOVE, LIVE AND BREATHE REGULATORY AFFAIRS

Progress Pharma adopts a business model for asset-centric drug development, aimed at advancing pharmaceutical assets beyond POC/Phase I/Phase II with venture money. Our deepest expertise resides in gastro-enterology, pain, immunology, dermatology, urology and women’s health. Progress Pharma conducts the due diligence on potential assets, develops the development and business plans, brings the co-investors to the table, runs the project in a cost-efficient manner and paves the way for the next future of the venture – whether it is a new investment round, IPO, a trade sale or licensing, …

www.ovizio.com

www.phara-consulting.be

www.progresspharma.eu

Rue Engeland 555(Domaine Latour de Freins)1180 Brussels Belgium

Phone: +32 2 600 50 90

Hopland 47/B72000 Antwerp Belgium

Phone: +32 3 293 90 84

Oude Baan 342350 Vosselaar Belgium

Phone: +32 14 76 23 21 WW

W.B

ELG

IUM

ATBI

OUS

.BE

21

PROMETHERA

SYNGULON

SYNOLYNE PHARMA

Promethera Biosciences S.A. is a biopharmaceutical company whose mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogeneic progenitor cells from healthy human liver tissue.

Promethera develops two products based on a newly discovered cell type isolated from healthy adult human livers : the human Heterologous Adult Liver-Derived Progenitor Cells (“hHALPC”) : • HepaStem : cell therapy product • H2Screen & H3Screen : screening tool

Syngulon is developing original genetic technologies to improve the efficiency of microorganisms involved in industrial bioproduction. Microbial bio-based products require deep genetic engineering (Synthetic Biology) of industrial microbial genomes to achieve high production yield and improve compatibility with the environment due to production in (semi-) open plants. Syngulon is developping genetic technologies focused on:• Security issues• Gene containment• Increase of the production yield

Synolyne Pharma is a lifescience company located in Liège (Belgium). It is (co)developing advanced chitosan-based biomaterials for therapeutic applications, the first of which being an injectible medical device for the treatment of arthritis, followed by devices for wound care, hemostasis, regenerative medicine, etc. It is also manufacturing KiOmedine, a pioneering GMP ultra-pure animal-free chitosan and chitosan derivatives.

www.promethera.com

www.syngulon.com

www.synolyne-pharma.com

Watson & Crick HillRue Granbonpré 111435 Mont-Saint-Guibert Belgium

Phone: +32 10 39 43 00

Rue Clément Ader 166041 Gosselies Belgium

Rue Haute Claire 44040 Herstal Belgium

Phone: +32 4 259 85 00

YNGULONMicrobialfermentationtechnologiesfor bio-basedproducts

SYNOLYNE PHARMA

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

22

TARGETOME

TELELINGUA

THERASOLVE

Targetome is a preclinical-stage biopharmaceutical company providing services in “biomarker discovery”, and developing its own antibodies against cancer.Our platform is based on a patented biomarker discovery technology, targeting “surface accessible” biomarkers using proprietary protein tagging techniques.Targetome is therefore very efficient to find relevant NOVEL biomarkers for pathologies such as cancer, inflammatory, CNS, metabolic diseases, etc, including for companion diagnostic purposes.

Telelingua project manages translations of every kind, so besides translating documents in every language combination, we also offer all other services related to translation, i.e. terminology management, quality control, localization, creating and managing translation memories, advice on internationalization, technical advice, developing automation tools for document management, multilingual typesetting, document legalization, printing and distribution, and multilingual IT testing. For the pharma and CRO industry, we translate clinical studies, protocols, observation notes, patient information leaflets, scientific and product notices, product brochures, scientific articles, training material, documentation, newsletters, rapid reference guides.

TheraSolve is a Belgian medical technology company developing innovative, user-friendly, and cost-effective solutions to promoting medication adherence. Non-adherence is a highly prevalent problem that severely impacts treatment outcomes. The MemoPatch® technology supports and motivates patients to take their medications in a timely fashion. Focused therapy groups are e.g. Oncology, Hepatitis C, HIV, Post-Transplant, Parkinson’s, Alzheimer’s, MS, Glaucoma, Diabetes.

www.targetome.be

www.telelingua.be

www.therasolve.com

GIGA EE1 - Traverse de l’Hôpital 54000 Liège Belgium

Phone: +32 4 266 94 95

Avenue Albert Lancaster 79a1180 Brussels Belgium

Phone: +32 2 373 68 68

Agoralaan Building A bis3590 Diepenbeek Belgium

Phone: +32 11 28 69 75

SolveThera

WW

W.B

ELG

IUM

ATBI

OUS

.BE

23

THROMBOGENICS

TIGENIX

TOXIKON EUROPE

ThromboGenics is dedicated to developing and commercializing new pharmacologic treatments thataddress important unmet clinical needs in ophthalmologyand oncology.

By delivering on this goal ThromboGenics intends to assist clinicians around the world to continually improve treatment for patients with sight threatening ophtalmic disorders and cancer.

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one product on the market and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the first product to be approved and obtain national reimbursement in Europe. ChondroCelect is currently on the market in Belgium, the Netherlands, Spain, the UK and Finland and benefits from full national reimbursement in 3 of these countries.

Toxikon contract laboratory provides comprehensive services for all stages of product development, from concept to final product. The scientific approach of our experienced staff provides customised studies for the pharmaceutical and biotechnology industries, including preclinical testing, bio-analytical method development and validation, stability studies, extractables & leachables and rapid microbiological services.

www.thrombogenics.com

www.tigenix.com

www.toxikon.be

Gaston Geenslaan 23001 Leuven Belgium

Phone: +32 16 75 13 10

Romeinsestraat 12 PO Box 23001 Leuven Belgium

Phone: +32 16 39 60 60

Romeinsestraat 123001 Leuven Belgium

Phone: +32 16 40 04 84

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

24

TRINEAN

TURNSTONE COMMUNICATIONS

UCB

Trinean is a Belgium based instrumentation company, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform.The company commercializes two instruments, the Xpose and the DropSense96®, analysing up to 96 samples, using microfluidic chips for standardized sample analysis. The Trinean platform is complemented with a software toolbox (including cDrop™) for improved data interpretation and lab-automation.

We are the expert in no-nonsense communicationsfor the life sciences sector.From strategic plan to final development and implementation – Turnstone Communications is optimally positioned to help you. Because we understand your product, R&D and business development path. That isn’t everything; we also have direct contacts in the target groups that matter themost – physicians, patient organizations, regulators, politicians, journalists, financiers…And we can help you organize your events.

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the centralnervous system.With 8700 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013.UCB is listed on Euronext Brussels (symbol: UCB).

www.trinean.com

www.turnstone.be

www.ucb.com

Dulle Grietlaan 17/39050 Gentbrugge Belgium

Phone: +32 9 272 75 35

Voorhavenlaan 14 A9000 Ghent Belgium

Phone: +32 9 218 71 97

Allée de la Recherche 601070 Brussels Belgium

Phone: +32 2 559 99 99 WW

W.B

ELG

IUM

ATBI

OUS

.BE

25

UCL

UGENT TECHTRANSFER

ULB

Founded in 1425, Université catholique de Louvain (UCL) is one of the oldest universities in the world.UCL is a complete university including 3 sectors(Medical Sciences, Science and Technology, Humanities and Social Sciences), bringing together over 4,000 researchers and benefiting from 3 scientific parks and 2 university hospitals (1,600 beds). Research is one of the driving forces of UCL, with about 1,000 research contracts signed each year with companies, publicand international bodies.The Louvain Technology Transfer Office (LTTO) has a longstanding experience in technology transfer.UCL has fostered 67 spin-offs since 1986.

UGent TechTransfer manages the intellectual property of Gent University, drives the use of that intellectual property through the creation of spin-offs and licensing, and supports the UGent research community in creating research collaborations with industry. Following its pioneering role in biotech development in Flanders starting forty years ago, UGent now can present an impressive track record with centers of excellence in agricultural, medical and industrial applications, and several successful spin-off companies.

Four scientific Nobel Prizes (of which the 2013 Prize in Physics), one Fields Medal, three Wolf Prizes and two Marie Curie Prizes are further evidence of ULB longstanding tradition of excellence. ULB is a major university located in the heart of Brussels (25,000 students and 500 research units). Its biotechnology research activities are led in top level research units located in up-to-date facilities in Brussels and Charleroi, with a science park around two Institutes: for Biology and Molecular Medicine, and for Medical Immunology. ULB also relies upon a network of one academic hospital and several university hospitals. 33 successful spin-off companies have emerged so far from ULB research activities.

www.uclouvain.be/en-recherche

www.techtransfer.ugent.be

www.ulbtto.be

Place de l’Université 11348 Louvain-la-Neuve Belgium

Phone: +32 10 47 24 98

Bollebergen 2B9052 Ghent Belgium

Phone: +32 9 264 78 83

Avenue F. D. Roosevelt 50 CP1611050 Brussels Belgium

Phone: +32 2 650 96 56

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

26

ULG (UNIVERSITY OF LIEGE)

UMONS

UNAMUR (UNIVERSITY OF NAMUR)

The University of Liège (ULg) has merged education, research and business within itsLife Sciences initiative GIGA, an innovative cluster integrating an academic research center, close clinical cooperation, technology facilities, space for both biotech start-ups and growing companies, and a biotech training centre. ULg is also renowned for its research in medical imaging (CRC), in cell therapy (LTCG), in protein engineering (CIP) and in agronimical sciences (Gembloux Agro-Bio Tech).

The University of Mons (UMONS) counts more than 5000 students, 1200 employees and about 700 researchers working in 10 institutes. Thanks to the help of EU funds, UMONS created four independent research centers focused on new materials (Materia Nova and INISMA) and on ICTs (Multitel and CETIC). Research is one of the university’s key missions and UMONS is involved in basic and applied research programs at both the European and international levels.

UNamur develops high-quality scientific research in human, social, natural sciences and medicine, both fundamental and applied. UNamur excels in nanotechnology, biotechnology, physics and chemistry of surfaces, and informatics. A multidisciplinary institute NARILIS gathers expertise in biology, physics, chemistry, informatics, and social sciences. UNamur has set up a strong program for technology transfer and spin-off companies have been created based on its research activities.

www.ulg.ac.be

www.umons.ac.be

www.unamur.be/en/research

Interface Entreprises-Université de Liège Espace Eurêka - Liège Science Park Avenue Pré-Aily 44031 Liège Belgium

Phone: +32 4 349 85 10

Place du Parc 207000 Mons Belgium

Phone: +32 65 37 47 78

Rue de Bruxelles 615000 Namur Belgium

Phone: +32 81 72 41 11 WW

W.B

ELG

IUM

ATBI

OUS

.BE

27

UNIVERCELLS

UNIVERSITY OF ANTWERP

VIB

Univercells is a provider of “Start-to-finish” bio manufacturing solutions, including the process design and selection of best technologies, Clinical plan design, process development, transfer of technology (process, training, quality system), facility design, manufacturing single-use technologies, facility construction and facility operation. Univercells is also developing and patenting a new concept of chaining of three process steps in stimulated continuous mode: cell culture under perfusion, clarification and capture. And also it targets mainly for low cost manufacturing of antigens/vaccines, Mabs and recombinant therapeutic proteins. Univercells positions itself as a global manager from A to Z and a supplier/integrator of the best USP, DSP and filing technologies on the market.

UAntwerpen research has proven to meet the highest standards of quality. They strongly believe in sharing their knowledge through open innovation and research collaboration. In life sciences UAntwerpen houses centers of excellence in molecular neurosciences and in vaccines and infectious diseases. Their core facilities in proteomics, bio-imaging, microscopic imaging, brain bio banking and genetic sequencing offer open access to third parties to state-of-the-art infrastructure and specialist expertise.

VIB is a life sciences research institute in Flanders, Belgium. VIB has more than 1300 scientists originating from over 60 countries. VIB is also an entrepreneurial biotechnology catalyst focusing on translating basic scientific breakthroughs into pharmaceutical, agricultural and industrial applications. In this context, VIB pro-actively translates biological insights into proof-of-concept stage assets which can be the basis for active partnering with industrial players or the launch of new Venture Capital-backed biotechnology companies.VIB has a close partnership with four Flemish universities - Ghent University, KU Leuven, University of Antwerp,and Vrije Universiteit Brussel.

www.univercells.com

www.uantwerpen.be/techtransfer

www.vib.be

Avenue Victor Jacobs 801040 Brussels Belgium

Phone: +32 2 318 83 48

Middelheimlaan 12020 Antwerp Belgium

Phone: +32 3 265 30 99

Rijvisschestraat 1209052 Zwijnaarde Belgium

Phone: +32 9 244 66 11

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

28

WBC INCUBATORWBC Incubator is the bio-incubator of Wallonia.Its mission is to stimulate the creation and the maturation of biotech companies based on R&D activities performed in academic institutions and industrial companies.Using financial, commercial and managerial resources, WBC Incubator aims to create value by enhancing the convergence of scientists, entrepreneurs and investors toward the expansion of a sustainable biotech industry in Wallonia.

www.wbc-incubator.be

Avenue de l’Hôpital 11CHU-GIGA- B344000 Liège Belgium

Phone: +32 4 246 51 10

WW

W.B

ELG

IUM

ATBI

OUS

.BE

29

OrganizersBelgianPavilion

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

30

BIOWIN

BRUSSELS INVEST & EXPORT

FLANDERS INVESTMENT & TRADE

BioWin is the health cluster of Wallonia, a region of Belgium (South of Brussels). Created in July 2006, its ambition is to federate all stakeholders from Wallonia participating in innovation and training in the fields of health biotechnologies and medical technologies. BioWin brings together more than 500 members (companies, universities and research centers) covering key technological areas of which radiation applications, biopharmaceutical, immunology, cell therapy and in vitro diagnostics.

Brussels Invest & Export is the foreign trade and investment agency of the Brussels Capital Region. Our mission is to help Brussels-based companies find their way to international markets as well as acting as a one-stop shop to welcome foreign investors in Brussels, which is the ideal launching pad for their exports across Europe. A team of almost 90 economic and commercial attachés are posted abroad and provide free guidance to Brussels-based SME’s all over the world.

Flanders Investment & Trade is the government agency supporting home-based companies doing business abroad and foreign companies looking to set up or expand operations in Flanders, the northern region of Belgium.

www.biowin.org

www.brusselsinvestexport.be

www.flandersinvestmentandtrade.com

Point CentreAvenue Georges Lemaître 196041 Gosselies (Charleroi) Belgium

Phone: +32 71 37 63 86

Avenue Louise 50 b41050 Brussels Belgium

Phone: +32 2 800 40 00

Koning Albert II laan 37 1030 Brussels Belgium

Phone: +32 2 504 87 11 WW

W.B

ELG

IUM

ATBI

OUS

.BE

FLANDERSINVESTMENT & TRADE

31

FLANDERSBIO

IMPULSE.BRUSSELS

LIFETECH.BRUSSELS

FlandersBio, the networking organization for the life sciences sector in Flanders, counts more than 280 members. FlandersBio supports and facilitates the sector’s sustained development to ensure that life sciences remains a strong driver for the economic growth in the region. By organizing networking activities we facilitate the transfer of knowledge between the different actors. FlandersBio assists you in finding your partner within the network of life sciences actors, e.g. expert centers, life sciences companies, Venture Capitalists, research organizations, subsidy agencies, etc.

impulse.brussels (formerly known as BEA-Brussels Enterprise Agency) offers to foreign investors, local start-ups and SMEs support in areas such as starting up, financing, public grants, town planning regulations, environmental permits,...In addition impulse.brussels encourages business competitiveness through innovation and internationalization and gives intensive support to high-potential companies in the areas of ICT and digital media, life sciences, green technologies and ecoconstruction.

lifetech.brussels gathers more than 100 innovative companies active in life sciences, 3 universities, 5 university hospitals, 4 incubators and a variety of public support organizations. Its aim is to increase the visibility of the Brussels know-how, to stimulate innovation, to encourage international partnerships, to generate synergies and to ensure that life sciences remain a strong driver of economic growth in the region, attracting new R&D companies, investors and innovative services providers.

www.flandersbio.be

www.impulse.irisnet.be

www.lifetechbrussels.com

Jean-Baptiste de Ghellincklaan 13 bus 01029051 Ghent Belgium

Phone: +32 9 241 80 41

Tour & TaxisAvenue du Port 86c b2111000 Brussels Belgium

Phone: +32 2 422 00 20

Tour & TaxisAvenue du Port, 86c b2111000 Brussels Belgium

Phone: +32 2 422 00 31

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

32

WALLONIA FOREIGN TRADE AND INVESTMENT AGENCY (AWEX)The Wallonia Foreign Trade and Investment Agency is responsible for export promotion of Wallonia-based companies and foreign investment attraction inWallonia, Belgium.

www.investinwallonia.be

Place Sainctelette 21080 Brussels Belgium

Phone: +32 2 421 85 86

WW

W.B

ELG

IUM

ATBI

OUS

.BE

33

BELG

IAN

BIO

TECH

- BI

O 2

013

PartnersBelgianPavilion

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

34

WW

W.B

ELG

IUM

ATBI

OUS

.BE

BIO.BE

PHARMA.BE

WALLONIA REGION TECHNOLOGY DEVELOPMENT DEPARTMENT

Bio.be is the Belgian biotechnology industry organization. Bio.be represents the companies and professionals involved in research, development, testing, production or marketing of biotechnology applications, as well as those servicing the biotechnology community.

pharma.be is the Belgian Pharmaceutical Industry Association which represents 140 innovative (bio) pharmaceutical companies. Our mission is to promote a better human healthcare through therapeutic innovation. The association’s top priority is to give patients the earliest possible access to tomorrow’s research and development-driven medicines.

Through its Technology Development Department, the Wallonia Region has designed a series of incentives to boost regional innovation and research and to meet the needs of all companies, from start-ups to well-established enterprises.

Wallonia’s R&D incentives include : • Grants for basic industrial research (up to 80% R&D costs) ;• Recoverable advances for applied research (up to 75% R&D costs) ;• Other possibilities includes grants for feasibility studies

or patent deposits.

www.bio.be

www.pharma.be

http://recherche-technologie.wallonie.be

Boulevard Auguste Reyers 80 (Diamant Building)1030 Brussels Belgium

Phone: +32 2 238 98 44

Chaussée de la Hulpe 1661170 Brussels Belgium

Phone: +32 2 661 91 02

Place de la Wallonie 15100 Namur Belgium

Phone: +32 81 33 45 62 WW

W.B

ELG

IUM

ATBI

OUS

.BE

35

BELG

IAN

BIO

TECH

- BI

O 2

013

Trade &InvestmentOffices

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

36

WW

W.B

ELG

IUM

ATBI

OUS

.BE

Djazia Filoso (Wallonia) atlanta@awex-wallonia.com

Wim Van Cauteren (Brussels & Flanders) atlanta@fitagency.com

ATLANTA

Baudouin de Hemptinne (Wallonia) sanfrancisco@awex-wallonia.com

Eric Gabrys (Brussels - Technology Attaché) california@brusselsinvestexport.com

Tonia Van de Vyver (Flanders) losangeles@fitagency.com

LOS ANGELES & SAN FRANCISCO

Luc Lippens (Brussels) newyork@brusselsinvestexport.com

Edith Mayeux (Wallonia) newyork@awex-wallonia.com

Benoit Reinards (Flanders - Investment) newyork@fitagency.com

Marc Struyvelt (Flanders) newyork@fitagency.com

Jan Wauters (Flanders - Technology Attaché) jan.wauters@fitagency.com

NEW YORK

Bernard Geenen (Brussels & Wallonia) washington@awex-wallonia.com

WASHINGTON

CHICAGOGilles Philippart de Foy (Wallonia) chicago@awex-wallonia.com

Jean-Pierre Vasaune (Wallonia - Investment) jpvasaune@investinwallonia.be

Piet Morisse (Flanders & Brussels) chicago@fitagency.com

Claude Stomp (Flanders - Investment) chicago@fitagency.com

Yves Dubus (Brussels & Wallonia) houston@awex-wallonia.com

HOUSTON

WW

W.B

ELG

IUM

ATBI

OUS

.BE

37

BELG

IAN

BIO

TECH

- BI

O 2

013

NOTES

BELG

IAN

BIO

TECH

- BE

LGIU

M@

BIO

201

4

38

The Belgian Pavilion is organized by :

Partners :

Des

ign:

iciL

aba.

be •

Prin

ted

in B

elgi

um

FLANDERSINVESTMENT & TRADE

www.belgiumatbious.be

BELGIUM@BIO